Myrcludex B is an experimental drug for the treatment of hepatitis B and D. The hepatitis B virus uses its surface lipopeptide pre-S1 for docking to mature liver cells via their sodium/bile acid cotransporter (NTCP) and subsequently entering the cells. Myrcludex B is a synthetic N-acylated pre-S1 that can also dock to NTCP, blocking the virus's entry mechanism.
Myrcludex B, also known as Bulevirtide, is a synthetic lipopeptide derived from the preS1 domain of the hepatitis B virus (HBV) large envelope protein. It is engineered to specifically target and bind to the sodium taurocholate co-transporting polypeptide (NTCP), a key receptor on hepatocytes responsible for the entry of both HBV and hepatitis D virus (HDV) into liver cells. Myrcludex B is characterized by its high specificity and affinity for NTCP, which underpins its unique mechanism of action in blocking viral entry. The compound's stability, ease of synthesis, and compatibility with a range of in vitro and in vivo experimental systems make it a valuable tool for researchers investigating viral hepatotropism, host-pathogen interactions, and liver-targeted drug delivery strategies.
Viral Entry Inhibition Research: Myrcludex B is widely utilized in studies focused on elucidating the mechanisms of HBV and HDV entry into hepatocytes. By competitively inhibiting the interaction between the viruses and NTCP, it allows researchers to dissect the early steps of infection and to map the molecular determinants critical for viral attachment and penetration. This application is instrumental in identifying novel therapeutic targets and in screening for additional entry inhibitors, thereby advancing the understanding of viral pathogenesis and informing the development of next-generation antiviral agents.
NTCP Function Characterization: As a selective NTCP ligand, Bulevirtide serves as a powerful probe for exploring the physiological and pathological roles of NTCP beyond viral entry. Research employing this peptide has shed light on NTCP's involvement in bile acid transport, cholesterol metabolism, and the regulation of hepatic homeostasis. By modulating NTCP activity, scientists can investigate the downstream effects on hepatocellular function, bile acid signaling pathways, and metabolic networks, providing insights into liver biology and the etiology of cholestatic and metabolic liver diseases.
Drug Transport and Pharmacokinetics Studies: The interaction of Myrcludex B with NTCP is leveraged to study the transporter's role in hepatic drug uptake and disposition. It enables the assessment of how NTCP-mediated transport influences the pharmacokinetics of various endogenous and exogenous compounds, including bile acids, drugs, and xenobiotics. Such studies are critical for predicting drug-drug interactions, optimizing hepatic drug targeting, and designing safer, more effective therapeutic regimens for liver-associated disorders.
Liver-Targeted Delivery Systems: The NTCP specificity of Bulevirtide is exploited in the development of novel liver-targeted drug delivery platforms. By conjugating therapeutic molecules or nanoparticles to Myrcludex B or its derivatives, researchers can achieve selective delivery to hepatocytes, thereby enhancing the efficacy and minimizing the off-target effects of bioactive agents. This approach holds promise for advancing precision medicine strategies in the treatment of liver diseases and for improving the therapeutic index of hepatotropic drugs.
Cellular and Animal Model Development: Myrcludex B is employed in the generation and validation of cellular and animal models of HBV and HDV infection. By modulating NTCP function, it allows for the creation of infection-resistant or infection-permissive models, which are invaluable for studying viral life cycles, host immune responses, and the efficacy of antiviral interventions. These models facilitate preclinical research and accelerate the translation of basic scientific discoveries into therapeutic innovations.
In summary, Myrcludex B stands out as a multifaceted research tool with broad applications in virology, hepatology, pharmacology, and drug delivery. Its ability to specifically target NTCP enables detailed investigations into viral entry mechanisms, NTCP biology, hepatic drug transport, and targeted therapeutic strategies. By supporting the development of advanced experimental models and precision delivery systems, Bulevirtide continues to drive progress in liver disease research and the broader field of molecular medicine.
2. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis
4. Cationic cell-penetrating peptides are potent furin inhibitors
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More